| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 08/30/2001 | CA2397234A1 Novel use of phenylheteroalkylamine derivatives |
| 08/30/2001 | CA2396960A1 Novel use of phenylheteroalkylamine derivatives |
| 08/30/2001 | CA2394088A1 Method for transdermal or intradermal delivery of molecules |
| 08/29/2001 | EP1127883A2 Oxamides as IMPDH inhibitors |
| 08/29/2001 | EP1127869A1 Novel compounds and medicinal use thereof |
| 08/29/2001 | EP1127580A2 Method of increasing the bioavailability and tissue penetration of azithromycin |
| 08/29/2001 | EP1127579A2 Method for increasing bioavailability of oral pharmaceutical compositions |
| 08/29/2001 | EP1127573A1 Compostitions and methods for treating osteoporosis |
| 08/29/2001 | EP1127567A2 Aqueous dispersions of water insoluble organic sunscreens |
| 08/29/2001 | EP1127168A2 Method for determining the susceptibility to developing sepsis and therapeutics for the treatment of sepsis |
| 08/29/2001 | EP1127129A1 Myosin heavy chain homolog |
| 08/29/2001 | EP1127123A2 Cell surface glycoproteins |
| 08/29/2001 | EP1127076A2 Crystallized form of fc epsilon receptor alpha chain, its 3-d model and uses thereof |
| 08/29/2001 | EP1127074A1 Methods for determining whether a compound is capable of inhibiting the interaction of a peptide with rage |
| 08/29/2001 | EP1127069A2 Biological materials and methods useful in the diagnosis and treatment of prion diseases |
| 08/29/2001 | EP1127054A1 Novel inhibitors of impdh enzyme |
| 08/29/2001 | EP1126884A2 Radiodense compositions |
| 08/29/2001 | EP1126880A2 Combination therapy of angiotensin converting enzyme inhibitor and aldosterone antagonist for reducing morbidity and mortality from cardiovascular disease |
| 08/29/2001 | EP1126873A1 Method for enhancing proliferation of inner ear hair cells using ligands for her2 and/or her3 receptors |
| 08/29/2001 | EP1126871A2 Combination therapy with vip antagonist |
| 08/29/2001 | EP1126865A2 Methods and compositions for treating or preventing peripheral neuropathies |
| 08/29/2001 | EP1126863A1 Vascular endothelial growth factor-like protein from orf virus nz2 binds and activates mammalian vegf receptor-2 |
| 08/29/2001 | EP1126850A1 Treatment of disorders of the outer retina |
| 08/29/2001 | EP1126849A1 Heterocyclic potassium channel inhibitors |
| 08/29/2001 | EP1126846A1 Use of a nicotine receptor agonist in the treatment of obsessive compulsive disorder |
| 08/29/2001 | EP1126845A2 New use of immunosuppressants for mmp-mediated diseases |
| 08/29/2001 | EP1126842A2 Inhibition of the formation of vascular hyperpermeability |
| 08/29/2001 | EP1126841A1 Method of treating migraines and pharmaceutical compositions |
| 08/29/2001 | EP1126840A1 5ht(1) receptor agonists and metoclopramide for the treatment of migraine |
| 08/29/2001 | EP1126838A1 Nitrosated and nitrosylated nonsteroidal antiinflammatory compounds, compositions and methods of use |
| 08/29/2001 | EP1126836A1 Benzamide potassium channel inhibitors |
| 08/29/2001 | EP1126835A1 Method for preventing increased iridial pigmentation during prostaglandin treatment |
| 08/29/2001 | EP1126832A2 Conductance of improperly folded proteins through the secretory pathway |
| 08/29/2001 | EP1126830A1 Pharmaceutical preparations for external use containing non-steroidal anti-inflammatory and analgesic agents |
| 08/29/2001 | EP1126822A1 Controlled release liquid delivery compositions with low initial drug burst |
| 08/29/2001 | EP1126812A1 Treatment of skin with adenosine or adenosine analog |
| 08/29/2001 | EP1126762A1 Energetic rehydration fluid composition in particular for young animals no longer able to digest milk normally |
| 08/29/2001 | EP1033985A4 Stable ascorbic acid preparation for topical use |
| 08/29/2001 | EP0914043A4 Implantable agarose-collagen beads containing cells which produce a diffusible biological product, and uses thereof |
| 08/29/2001 | EP0904299B1 Synthetic polysaccharides, method for preparing same and pharmaceutical compositions containing said polysaccharides |
| 08/29/2001 | EP0876141B1 Preparations of non-steroidal analgesics |
| 08/29/2001 | EP0751709B1 Use of bcl-2 for the manufacture of medicaments for the therapeutic treatment and prevention of diseases |
| 08/29/2001 | CN1310629A Coadministration of ACAT and MMP inhibitors for the treatment of atherosclerotic lesions |
| 08/29/2001 | CN1310627A Hair growth/maintenance compositions and methods involving the same |
| 08/29/2001 | CN1310625A Use of alpha1 & beta1 integrin receptor inhibitors and TGF-beta1 inhibitors in the treatment of kidney disease |
| 08/29/2001 | CN1310623A Bioimplant formulation |
| 08/29/2001 | CN1310620A Use of glucose uptake enhancer for reducing apoptosis |
| 08/29/2001 | CN1310619A Use of glucose uptake enhancer for reducing post-ischemic injury of the heart |
| 08/29/2001 | CN1310618A Inhibition of binding of Hox and homeodomain containing proteins and uses thereof |
| 08/29/2001 | CN1310613A Rapidly disintegrable solid preparation |
| 08/29/2001 | CN1310610A Pharmaceutical composition in particular for preventing and treating mucositis induced by radiotherapy or chemotherapy |
| 08/29/2001 | CN1310195A Aqueous dispersion body of water insoluble organic ultraviolet ray filtering material |
| 08/29/2001 | CN1310179A Oxamide being as IMPDH inhibitor |
| 08/29/2001 | CN1309970A Application of uridine phosphorylase inhibitor and composition containing the same |
| 08/28/2001 | US6281252 Administering a aliphatic amine polymer; therapy for kidney stones |
| 08/28/2001 | US6281244 Therapy for transplant rejection |
| 08/28/2001 | US6281239 Tissue softening composition containing urea and an antifungal composition |
| 08/28/2001 | US6281227 Inhibitors of the activity of factor xa. |
| 08/28/2001 | US6281225 Inhibiting proliferation of arterial smooth muscle cells |
| 08/28/2001 | US6281207 Treatment of movement disorders by administration of mirtazapine |
| 08/28/2001 | US6281193 In autoimmune diseases in general, or graft-versus-host reactions in particular. |
| 08/28/2001 | US6281012 Preventing graft versus host disease |
| 08/28/2001 | US6280966 Indicators of altered mitochondrial function in predictive methods for determining risk of type 2 diabetes mellitus |
| 08/28/2001 | US6280957 Preventing graft rejection in humans; administer human a modulator of ligand activity, insert hematopoietic stem cells and graft into human, monitor response to grafts |
| 08/28/2001 | US6280953 Methods to identify polynucleotide and polypeptide sequences which may be associated with physiological and medical conditions |
| 08/28/2001 | US6280774 Extraction of bile from animals, stimulating monocytes and macrophages and modulating tumor necrosis factor production |
| 08/28/2001 | US6280764 Patch for therapy of acne |
| 08/28/2001 | US6280732 Administering intracerebrally al-1 immunoadhesin comprising mature al-1 polypeptide having specified amino acid sequence in amount effective to activate autophosphorylation of rek7 |
| 08/28/2001 | US6280730 Antibodies that bind to α2-antiplasmin crosslinked to fibrin which do not inhibit plasma α2-antiplasmin |
| 08/28/2001 | CA2178487C Local delivery of fibrinolysis enhancing agents |
| 08/28/2001 | CA2107552C Use of deprenyl to maintain, prevent loss, or recover nerve cell function |
| 08/28/2001 | CA2101572C Benzoxazinones as inhibitors of hiv reverse transcriptase |
| 08/24/2001 | CA2337588A1 Oxamides as impdh inhibitors |
| 08/23/2001 | WO2001061055A2 Methods for diagnosing, monitoring, staging, imaging and treating lung cancer via lung cancer specific genes |
| 08/23/2001 | WO2001061039A2 5-hydroxytryptamine transporter gene polymorphisms |
| 08/23/2001 | WO2001061017A2 Modified cytokines for use in cancer therapy |
| 08/23/2001 | WO2001061007A2 Fibroblast growth factor-23 molecules and uses thereof |
| 08/23/2001 | WO2001061000A1 5ht3 receptors of nematodes, polynucleotide molecules encoding same, and antagonists thereof |
| 08/23/2001 | WO2001060992A2 Human protein tyrosine phosphatase, encoding dna and uses thereof |
| 08/23/2001 | WO2001060991A2 Human kinases |
| 08/23/2001 | WO2001060979A1 Pancreatic islet cell growth factors |
| 08/23/2001 | WO2001060975A2 Gene disruption methodologies in fungi for drug target discovery |
| 08/23/2001 | WO2001060857A2 Compositions useful for regulating parkin gene activity |
| 08/23/2001 | WO2001060844A2 Peptide and nucleic acid coding therefor for the detection, diagnosis and therapy of diseases of the nervous system |
| 08/23/2001 | WO2001060827A1 Novel p-gp-inhibiting compounds |
| 08/23/2001 | WO2001060807A1 Aryloxyacetic acids for diabetes and lipid disorders |
| 08/23/2001 | WO2001060784A1 Aniline-derived ligands for the thyroid receptor |
| 08/23/2001 | WO2001060409A1 Improved paste formulations |
| 08/23/2001 | WO2001060408A2 Microcompetiton and human disease |
| 08/23/2001 | WO2001060407A2 Novel combination of non-sedative anti-histamines containing substances which influence the action of leukotriene, for treating rhinitis/conjunctivitis |
| 08/23/2001 | WO2001060400A2 Use of inhibitors of caspase-3 or caspase-activated desoxyribonuclease (cad) for treating cardiac disease |
| 08/23/2001 | WO2001060399A1 Diclofenac pharmaceutical composition based on vitamin-e, papain and hyaluronidase |
| 08/23/2001 | WO2001060397A1 Uses of agonists and antagonists to modulate activity of tnf-related molecules |
| 08/23/2001 | WO2001060396A2 Method for treating thyroid disorders |
| 08/23/2001 | WO2001060392A1 Oral, nasal and pulmonary dosage formualtions of copolymer 1 |
| 08/23/2001 | WO2001060369A1 Inhibitors of prenyl-protein transferase |
| 08/23/2001 | WO2001060367A1 Compositions comprising flavopiridol and their use for hiv therapy |
| 08/23/2001 | WO2001060366A1 Use of n-substituted-1,5-dideoxy-1,5-imino-d-glucitol compounds for treating hepatitis virus infections |
| 08/23/2001 | WO2001060365A1 Treatment or prevention of prostate cancer with a cox-2 selective inhibiting drug |
| 08/23/2001 | WO2001060358A1 Method and compositions for treating fibrotic diseases |